Cure Duchenne Blog Archives

Updates from World Muscle Society – 2020

September 28, 2020

9/28/20209/29/202010/1/202010/2/202010/3/2020 One of the scientific highlights of the fall season for CureDuchenne is the Annual International Congress of the World Muscle Society (WMS). This is the largest annual and international [...]

Google’s Project Euphonia

August 26, 2020

Get Involved with Project Euphonia Help future generations of people living with motor speech impairments. Automated speech recognition, which powers voice-activated technology such as the Google Assistant, are more common […]

Dyne Therapeutics Series B financing

August 12, 2020

CureDuchenne congratulates the incredible Dyne Therapeutics team, who recently announced closing $115M in equity financing to develop transformational therapies for patients with serious muscle diseases. We share this news in […]

blog-news-header-image-nationwide-childrens-dr-flanigan

Nationwide Children’s Hospital Begins New First-in-Human Clinical Study for DMD Using a Novel Gene Therapy Approach

July 30, 2020

CureDuchenne is very proud that Dr. Kevin Flanigan, at Nationwide Children’s Hospital, has treated two patients with gene therapy that carry the Duplication 2 mutation. CureDuchenne funded Dr. Flanigan’s very […]

EveryLife Survey – What’s the cost of rare disease to YOU?

July 7, 2020

Take this Survey by July 19! CureDuchenne is supporting the EveryLife Foundation for Rare Diseases in their effort to conduct a survey of families living with rare diseases. This survey […]

PFIZER’S NEW PHASE 1B RESULTS OF GENE THERAPY IN AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) SUPPORT ADVANCEMENT INTO PIVOTAL PHASE 3 STUDY

May 15, 2020

Friday, May 15, 2020 – 8:00amEDT Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy […]

Updates from ASGCT 2020

May 13, 2020

Tuesday - 5/12/2020Wednesday - 5/13/2020Thursday - 5/14/2020 The 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) kicked off on Tuesday, May 12 to a large [...]

CureDuchenne Ventures’ latest investment in Myosana Therapeutics

April 22, 2020

CureDuchenne Ventures is happy to announce its latest investment in Myosana Therapeutics, a new biotech company based in Seattle, WA. Myosana is aiming to develop next-generation gene therapy for Duchenne muscular dystrophy and other neuromuscular […]

Letter to the Community – Myosana Therapeutics

April 22, 2020

Dear Duchenne Community, I’m truly thrilled about our investment in a new biotech company called Myosana Therapeutics. Myosana aims to develop next-generation gene therapy for Duchenne muscular dystrophy and neuromuscular diseases. Because of this investment, the team is now positioned to conduct […]